Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TR2017/16086Aexternal-prioritypatent/TR201716086A1/en
Application filed by Neutec Ar Ge Sanayi Ve Ticaret Anonim SirketifiledCriticalNeutec Ar Ge Sanayi Ve Ticaret Anonim Sirketi
Priority claimed from TR2017/16203Aexternal-prioritypatent/TR201716203A1/en
Publication of TR201716238A1publicationCriticalpatent/TR201716238A1/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
Mevcut buluş solunum yollar hastalıklarının tedavisinde kullanılacak beklometazon ile bir ß-2 adrenerjik reseptör agonisti ve bir antikolinerjik etken madde kombinasyonunu içeren farmasötik bileşimlere ilişkindir.The present invention relates to pharmaceutical compositions for use in the treatment of respiratory tract diseases, comprising a combination of beclomethasone and a ß-2 adrenergic receptor agonist and an anticholinergic agent.
TR2017/16238A2017-10-182017-10-20
New pharmaceutical compositions.
TR201716238A1
(en)
Compound (r) -n- (3- (7-methyl-1h-indazol-5-yl) -1- (4- (1-methylpiperidin-4-yl) piperazin-1-yl) -1-oxopropan-2 -yl) -4- (2-oxo-1,2-dihydroquinolin-3-yl) piperidine-1-carboxamide; pharmaceutical composition that includes it; use of the compound for the treatment of migraine, neuropathic pain, breast cancer and glioma.
Crystalline form of (S) - (2- (6-XLPO-7-Methyl-1H-benzo [D] imidazol-2-yl) -2-methylpyrrolidin-1-yl) (5-Methoxy-2- (2-) 1,2,3-triazol-2-yl) phenyl) methanone and its use as an orexin receptor antagonist